GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Optipharm Co Ltd (XKRX:153710) » Definitions » Gross Profit

Optipharm Co (XKRX:153710) Gross Profit : ₩4,643 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Optipharm Co Gross Profit?

Optipharm Co's gross profit for the three months ended in Sep. 2024 was ₩1,307 Mil. Optipharm Co's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was ₩4,643 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Optipharm Co's gross profit for the three months ended in Sep. 2024 was ₩1,307 Mil. Optipharm Co's Revenue for the three months ended in Sep. 2024 was ₩4,786 Mil. Therefore, Optipharm Co's Gross Margin % for the quarter that ended in Sep. 2024 was 27.30%.

Optipharm Co had a gross margin of 27.30% for the quarter that ended in Sep. 2024 => Competition eroding margins

During the past 11 years, the highest Gross Margin % of Optipharm Co was 39.55%. The lowest was 23.22%. And the median was 29.75%.

Warning Sign:

Optipharm Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -9.6%.


Optipharm Co Gross Profit Historical Data

The historical data trend for Optipharm Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optipharm Co Gross Profit Chart

Optipharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,501.68 3,509.05 3,738.29 3,716.58 4,197.21

Optipharm Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,051.92 1,475.16 844.13 1,017.07 1,306.82

Competitive Comparison of Optipharm Co's Gross Profit

For the Diagnostics & Research subindustry, Optipharm Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Optipharm Co's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Optipharm Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Optipharm Co's Gross Profit falls into.



Optipharm Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Optipharm Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=17372.568 - 13175.363
=4,197

Optipharm Co's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=4786.217 - 3479.396
=1,307

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩4,643 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Optipharm Co's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=1,307 / 4786.217
=27.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Optipharm Co  (XKRX:153710) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Optipharm Co had a gross margin of 27.30% for the quarter that ended in Sep. 2024 => Competition eroding margins


Optipharm Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Optipharm Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Optipharm Co Business Description

Traded in Other Exchanges
N/A
Address
6, 63 Osong, Hwaseong-eup, Heungduk-gu, Chungcheongbuk-do, Cheongju, KOR
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.

Optipharm Co Headlines

No Headlines